Kainos Medicine, Inc.

Equities

A284620

KR7284620002

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
2,895 ^KRW	-5.08%		+7.02%	-32.99%

2023	Kainos Medicine, Inc.(KOSDAQ:A284620) dropped from S&P Global BMI Index	CI
2022	Kainos Medicine, Inc. announced that it has received KRW 2.00000052 billion in funding from SC United Co., Ltd.	CI

Kainos Medicine, Inc. announced that it has received KRW 12.49997346 billion in funding from MAGNA Investment Co., Ltd., Axis Investment Co., Ltd., and other investors

November 10, 2021

On November 11, 2021, Kainos Medicine, Inc. closed the transaction. The transaction included participation from The Wells Urban Regeneration Investment Association which will acquire 561,797 shares, Korea Bio Unicorn Private Equity Joint Venture, Magna-Axis Tourism Venture Fund a fund managed by MAGNA Investment Co., Ltd. and Axis Investment Co., Ltd., MAGNA VITA Fund a fund managed by MAGNA Investment Co., Ltd., Samjong Kim,Kim, Chang-oh, Song, Yong-ok, Kwon, Sook-yong, Park, Ae-myung, Jin, young-dae, Lee, Kun-hwan, Choi, In-jae, Kwon, Hee-min, and Kwangjae Choi each acquiring 374,531 shares.

Latest news about Kainos Medicine, Inc.

Kainos Medicine, Inc.(KOSDAQ:A284620) dropped from S&P Global BMI Index	23-09-18	CI
Kainos Medicine, Inc. announced that it has received KRW 2.00000052 billion in funding from SC United Co., Ltd.	22-06-22	CI
Kainos Medicine, Inc. announced that it expects to receive KRW 2.00000052 billion in funding from SC United Co., Ltd.	22-06-14	CI
Kainos Medicine to Raise over $37 Million via Stock Sale	22-06-10	MT
Kainos Medicine, Inc. announced that it has received KRW 12.49997346 billion in funding from MAGNA Investment Co., Ltd., Axis Investment Co., Ltd., and other investors	21-11-10	CI
Kainos Medicine, Inc. announced that it expects to receive KRW 12.49997346 billion in funding	21-10-13	CI
Emmaus Life Sciences Acquires Key Intellectual Property Rights to Novel IRAK4 Inhibitor From Kainos Medicine	21-10-12	CI
Kainos Medicine, Inc.(KOSDAQ:A284620) added to S&P Global BMI Index	21-09-20	CI
Emmaus Life Sciences Announces Collaboration with Kainos Medicine for Preclinical Development of Irak4 Inhibitor as Potential Anti-Cancer Drug	21-03-02	CI
FAScinate Therapeutics, Inc. announced that it has received KRW 18.100000475 billion in funding from Kainos Medicine, Inc.	20-07-30	CI
Kainos Medicine, Inc. announced that it has received KRW 20 billion in funding from SC United Co., Ltd., NH Investment & Securities Co., Ltd., KB Securities Co.,Ltd, Asset Management Arm	20-06-29	CI
Kainos Medicine, Inc. announced that it expects to receive KRW 20 billion in funding from SC United Co., Ltd., NH Investment & Securities Co., Ltd., KB Securities Co.,Ltd, Asset Management Arm	20-06-25	CI
Kainos Medicine, Inc. completed the acquisition of Hana Financial Eleventh Special Purpose Acquisition Company in a reverse merger transaction.	20-06-07	CI
Kainos Medicine, Inc. agreed to acquire Hana Financial Eleventh Special Purpose Acquisition Company in a reverse merger transaction.	19-11-28	CI
Kainos Medicine, Inc. announced that it has received KRW 3.9999933 billion in funding from NH Investment & Securities Co., Ltd., and another investor	19-08-08	CI
Kainos Medicine, Inc. announced that it expects to receive KRW 3.9999933 billion in funding from NH Investment & Securities Co., Ltd., and another investor	19-07-29	CI
Kainos Medicine, Inc. announced that it has received KRW 2.9999934 billion in funding from DSC Investment Inc.	18-08-29	CI
Kainos Medicine, Inc. announced that it expects to receive KRW 2.9999934 billion in funding from DSC Investment Inc.	18-08-20	CI
Kainos Medicine, Inc. announced that it has received KRW 1.55 billion in funding	17-03-09	CI
Kainos Medicine, Inc. announced that it expects to receive KRW 1.55 billion in funding	17-03-08	CI

Chart Kainos Medicine, Inc.

Duration

Period

More charts

Company Profile

Kainos Medicine Inc is a Korea-based company mainly engaged in the research and development of pharmaceuticals. The Company is engaged in the research and development of degenerative brain disease treatments, antiviral drugs, anticancer drugs and other products. In addition, the Company is engaged in the research and development of Parkinson's disease drugs, AIDS drugs, blood anticancer drugs and other products.

Sector

Biotechnology & Medical Research

Calendar

2024-05-09 - Q1 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
KAINOS MEDICINE, INC.	-32.99%	58.73M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research